Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths.

Karaesmen E, Hahn T, Dile AJ, Rizvi AA, Wang J, Wang T, Haagenson MD, Preus L, Zhu Q, Liu Q, Yan L, Liu S, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, McCarthy PL, Pasquini MC, Spellman SR, Lee SJ, Paczesny S, Sucheston-Campbell LE.

Blood Adv. 2019 Aug 27;3(16):2512-2524. doi: 10.1182/bloodadvances.2019000075.

2.

Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.

Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Cereb N, Haagenson MD, Spellman SR, Lee SJ, Guethlein LA, Parham P, Miller JS, Cooley SA.

Biol Blood Marrow Transplant. 2019 May;25(5):949-954. doi: 10.1016/j.bbmt.2018.12.763. Epub 2018 Dec 27.

PMID:
30594542
3.

The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR.

Pingel J, Wang T, Hagenlocher Y, Hernández-Frederick CJ, Nagler A, Haagenson MD, Fleischhauer K, Hsu KC, Verneris MR, Lee SJ, Mohty M, Polge E, Spellman SR, Schmidt AH, van Rood JJ.

Bone Marrow Transplant. 2019 Jun;54(6):849-857. doi: 10.1038/s41409-018-0345-8. Epub 2018 Oct 2.

PMID:
30279575
4.

Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders.

Woolfrey A, Wang T, Lee SJ, Haagenson MD, Chen G, Fleischhauer K, Horan J, Hsu K, Verneris M, Spellman SR, Fernandez-Vina M.

Bone Marrow Transplant. 2019 Mar;54(3):494-496. doi: 10.1038/s41409-018-0334-y. Epub 2018 Sep 19. No abstract available.

5.

KIR Donor Selection: Feasibility in Identifying better Donors.

Weisdorf D, Cooley S, Wang T, Trachtenberg E, Haagenson MD, Vierra-Green C, Spellman S, Spahn A, Vogel J, Kobusingye H, Fehninger T, Woolfrey A, Devine S, Ross M, Waller EK, Sobecks R, Parham P, Guethlein LA, Marsh SGE, Miller J; participating center writing committee.

Biol Blood Marrow Transplant. 2019 Jan;25(1):e28-e32. doi: 10.1016/j.bbmt.2018.08.022. Epub 2018 Aug 24.

PMID:
30149149
6.

Patient HLA Germline Variation and Transplant Survivorship.

Petersdorf EW, Stevenson P, Malkki M, Strong RK, Spellman SR, Haagenson MD, Horowitz MM, Gooley T, Wang T.

J Clin Oncol. 2018 Aug 20;36(24):2524-2531. doi: 10.1200/JCO.2017.77.6534. Epub 2018 Jun 14.

7.

Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis.

William BM, Wang T, Haagenson MD, Fleischhauer K, Verneris M, Hsu KC, de Lima MJ, Fernandez-Viña M, Spellman SR, Lee SJ, Hill BT.

Biol Blood Marrow Transplant. 2018 Apr;24(4):827-831. doi: 10.1016/j.bbmt.2017.11.003. Epub 2017 Nov 16.

8.

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL.

N Engl J Med. 2017 Feb 9;376(6):536-547. doi: 10.1056/NEJMoa1611604.

9.

Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.

Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Trachtenberg E, Haagenson MD, Spellman SR, Ladner M, Guethlein LA, Parham P, Miller JS, Cooley SA.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1602-1607. doi: 10.1016/j.bbmt.2016.05.016. Epub 2016 May 21.

10.

Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes.

Nakasone H, Sahaf B, Tian L, Wang T, Haagenson MD, Schoenrock K, Perloff S, Ryan CE, Wu F, Spellman SR, Lee SJ, Ritz J, Miklos DB; Center for International Blood and Marrow Transplantation.

Haematologica. 2016 Jan;101(1):e30-3. doi: 10.3324/haematol.2015.134551. Epub 2015 Oct 22. No abstract available.

11.

High HLA-DP Expression and Graft-versus-Host Disease.

Petersdorf EW, Malkki M, O'hUigin C, Carrington M, Gooley T, Haagenson MD, Horowitz MM, Spellman SR, Wang T, Stevenson P.

N Engl J Med. 2015 Aug 13;373(7):599-609. doi: 10.1056/NEJMoa1500140.

12.

HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation.

Petersdorf EW, Gooley TA, Malkki M, Bacigalupo AP, Cesbron A, Du Toit E, Ehninger G, Egeland T, Fischer GF, Gervais T, Haagenson MD, Horowitz MM, Hsu K, Jindra P, Madrigal A, Oudshoorn M, Ringdén O, Schroeder ML, Spellman SR, Tiercy JM, Velardi A, Witt CS, O'Huigin C, Apps R, Carrington M; International Histocompatibility Working Group in Hematopoietic Cell Transplantation.

Blood. 2014 Dec 18;124(26):3996-4003. doi: 10.1182/blood-2014-09-599969. Epub 2014 Oct 16.

13.

Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.

Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SG, Spellman S, Haagenson MD, Saeturn K, Ladner M, Trachtenberg E, Parham P, Miller JS.

J Immunol. 2014 May 15;192(10):4592-600. doi: 10.4049/jimmunol.1302517. Epub 2014 Apr 18.

14.

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS.

Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20.

15.

Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis.

Sengsayadeth S, Wang T, Lee SJ, Haagenson MD, Spellman S, Fernandez Viña MA, Muller CR, Verneris MR, Savani BN, Jagasia M.

Biol Blood Marrow Transplant. 2014 Jun;20(6):900-3. doi: 10.1016/j.bbmt.2014.03.005. Epub 2014 Mar 14.

16.

Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.

Petersdorf EW, Malkki M, Horowitz MM, Spellman SR, Haagenson MD, Wang T.

Blood. 2013 Mar 7;121(10):1896-905. doi: 10.1182/blood-2012-11-465161. Epub 2013 Jan 10.

17.

MHC-resident variation affects risks after unrelated donor hematopoietic cell transplantation.

Petersdorf EW, Malkki M, Gooley TA, Spellman SR, Haagenson MD, Horowitz MM, Wang T.

Sci Transl Med. 2012 Jul 25;4(144):144ra101. doi: 10.1126/scitranslmed.3003974.

18.

Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T.

Blood. 2012 Jan 5;119(1):296-307. doi: 10.1182/blood-2011-06-364265. Epub 2011 Oct 18.

19.

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.

Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS.

Blood. 2010 Oct 7;116(14):2411-9. doi: 10.1182/blood-2010-05-283051. Epub 2010 Jun 25.

20.

Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype.

Tomblyn M, Young JA, Haagenson MD, Klein JP, Trachtenberg EA, Storek J, Spellman SR, Cooley S, Miller JS, Weisdorf DJ; CIBMTR Infection and Immune Reconstitution Working Committee.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1155-61. doi: 10.1016/j.bbmt.2010.02.024. Epub 2010 Mar 1.

21.

HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States.

Baxter-Lowe LA, Maiers M, Spellman SR, Haagenson MD, Wang T, Fernandez-Vina M, Marsh SG, Horowitz M, Hurley CK.

Biol Blood Marrow Transplant. 2009 Aug;15(8):971-81. doi: 10.1016/j.bbmt.2009.04.015.

22.

HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.

Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C, Nademanee A, McGlave P, Horowitz MM, Petersdorf EW.

J Clin Oncol. 2009 Apr 1;27(10):1644-52. doi: 10.1200/JCO.2008.18.7740. Epub 2009 Feb 17.

23.

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.

Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P, Haagenson MD, Kurian S, Klein JP, Horowitz MM, Confer DL.

Blood. 2009 Apr 9;113(15):3604-11. doi: 10.1182/blood-2008-08-175323. Epub 2009 Feb 3.

24.

Mapping MHC-resident transplantation determinants.

Malkki M, Gooley TA, Horowitz MM, Absi L, Christiansen FT, Cornelissen JJ, Dormoy A, Dubois V, Gagne K, Gluckman E, Haagenson MD, Oudshoorn M, Spellman S, Petersdorf EW; International Histocompatibility Working Group in Transplantation.

Biol Blood Marrow Transplant. 2007 Aug;13(8):986-95.

Supplemental Content

Loading ...
Support Center